SavedAdd your journal

Journals / Üroonkoloji Bülteni / 2017 / Cilt: 16 - Sayı: 3

Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer

Mesane Kanseri için İmmünoterapötik Potansiyele Sahip Mycobacterium Brumae Ekstresi Fraksiyonları

Zeliha Ertürk MD
Esra Büber MD
Haluk Özen MD
Ömür Çelikbıçak MD
Bekir Salih MD
N Leyla Açan MD
Pages
70–76
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These components have a potential to develop of new agents for NMIBC treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Immunotherapy with intravesical Bacillus Calmette-Guérin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects.
📊
Key Findings & Data:Samples prepared by aqueous solution and acetone were subjected to high performance liquid chromatography on reverse phase and strong ion exchange columns.
💡
Conclusion & Impact:Conclusion: These components have a potential to develop of new agents for NMIBC treatment
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Immunotherapy with intravesical Bacillus Calmette-Guérin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain. Materials and Methods: Immunostimulated and non-pathogenic Mycobacterium brumae strains resembling BCG with cytotoxic activities were used. The bacteria were sonicated after heat treatment. Samples prepared by aqueous solution and acetone were subjected to high performance liquid chromatography on reverse phase and strong ion exchange columns. Tumour necrosis factor-α (TNF-α) stimulating activities and the matrix-assisted laser desorption/ionization-mass spectroscopy findings of the samples were analysed. Results: As a result, it was revealed that two components, m/z ratios around 1800 and another around m/z 3600 could be responsible for TNF-α stimulating activity. Conclusion: These components have a potential to develop of new agents for NMIBC treatment

Özet

Amaç: Lokal ve sistemik yan etkilerine rağmen, yüksek riskli kasa invaziv olmayan mesane kanserinde (KİOMK) Bacillus Calmette-Guérin (BCG) uygulanması altın standart tedavidir. Biz mesane kanseri tedavisi için canlı suşlar yerine daha az toksik ve daha güçlü terapötik ajanlar geliştirmeyi hedefledik. Gereç ve Yöntem: İmmünostimülan ve sitotoksik aktiviteleri BCG ile benzerlik gösteren patojen olmayan Mycobacterium brumae suşu kullanıldı. Bakteriler ısı muamelesinden sonra sonike edildi. Sulu çözeltiyle ve asetonla ekstre edilerek hazırlanmış örnekler ters faz ve kuvvetli iyon değiştirici kolonlar kullanılarak yüksek performanslı sıvı kromatografisi uygulandı. Örneklerin tümör nekroz faktörü-? (TNF-?) uyarıcı aktiviteleri ve matriks-yardımlı lazer desorpsiyon-iyonlaştırmalı-kütle spektrometri çıktıları incelendi. Bulgular: Sonuç olarak, m/z oranları 1800 ve 3600 dolayındaki iki bileşenin TNF-? uyarıcı aktiviteden sorumlu olabileceği ortaya çıkarıldı. Sonuç: Bu bileşenler KİOMK tedavisi için yeni ajanlar geliştirme potansiyeline sahiptir

🔖

Cite This Article

MD, Z. E., MD, E. B., MD, H. Ö., MD, Ö. Ç., MD, B. S., MD, N. L. A. (2017). Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer. Üroonkoloji Bülteni, Cilt: 16 - Sayı: 3, 70–76. https://ajindex.com/articles/334351

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30
  2. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008
  3. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011;186:2158-2167
  4. Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;63:36-44
  5. Witjes JA, Palou J, Soloway M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742-750
  6. Brausi M, Olaru V. Management of high-risk non-muscle invasive bladder cancer. Minerva Urol Nefrol 2012;64:255-260
  7. Bishay JH, Park ES, Hemstreet GP. Intravesical immunotherapy: BCG. In: Lokeshwar VB, Merseburger AS, Hautmann SH, editors. Bladder Tumors: Molecular Aspects and Clinical Management, Cancer Drug Discovery and Development. Humana Press; 2011. p. 271-295
  8. Büber E, Keskin S, Açan NL. Importance of mycobacteria in treatment of bladder tumor. Bull Urooncol 2012;11:41-45
  9. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus CalmetteGuérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-472
  10. Filion, MC, Lépicier P, Morales A, et al. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br J Cancer 1999;79:229-235
  11. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001;166:1633-1637
  12. Orhan B,, Büber E, Keskin MS, et al. Therapeutic effects ofMycobacterium phleicell wall extracts. Turk J Med Sci 2012;42:193-199
  13. Keskin MS. M. phlei, M. smegmatis: the antitumoral effects of nonpathogen mycobacteria species, Hacettepe University, Ankara, Turkey: 2004
  14. Yuksel ZS, Buber E, Kocagoz T, et al. Mycobacterial strains that stimulate the immune system mos